Much ado about nothingIn Shakespeares play “Much ado about nothing” Hero's cousin Beatrice (a confirmed spinster) and Benedict (an eternal bachelor) are each duped into believing the other is in love with them. Claudio is deceived by a malicious plot and denounces Hero as unchaste before they marry.In other words along the way some believe they are duped, whilst others feel deceived. Yet in the end, in light of the truth, Hero and Claudio reunite with a happy ending, that being a double wedding between the two couples.
Sound familiar? It does to me. From where I sit it could be a plot from an Imugene play, wherein shareholders feel duped by Chairman Paul Hopper, who sold a parcel of shares near the top of the cycle, only to see the share price fall immeasurably thereafter. Or the perception by some that Imugene CEO Leslie Chong has deceived them by such phrases as “Our dance cards are full," and so on and so forth, with terms such as “excitement” and “exuberance” only adding to their perceived notion of deception. Miscommunication and assumptions can and often do lead to tragedy...
In the real world, placing fear and loathing aside, or feelings of paranoia, Imugene’s leaders have suffered far worse than the average punter, when it comes to IMU’s subsequent demise. Yet fundamentally the stock has a solid footing from which to move forward, toward the happy ending many shareholders have been waiting for. A closer look into Imugene’s performance in years of late reveals the following (in summary):
- Imugene releases positive results in their combination study with Eureka Therapeutics (visa vie Oncarlytics)
- Imugene releases positive results in their combination study with Celularity (visa vie Oncarlytics)
- Imugene releases positive results from their combination study with Blincyto (visa vie Oncarlytics)
- Imugene is awarded an FDA IND to progress with a Phase 1 in human Oncarlytics Trial in combination with Amgen’s Blincyto
- Imugene announces strong in patient results for their PD1 B cell treatment into late stage cancer patients including a complete response and several disease stabilisation response notification’s
- Imugene reach a 5 year supply agreement with Roche pharmaceuticals to progress the development of PD1 Vaxx in humans in combination with Roche’s successful Tercentriq drug
- Imugene present outstanding overall survival rates for late stage gastric patients dosed with their first immunotherapy vaccine Her Vaxx
- Imugene progress development of their leading B cell candidate Her Vaxx in combination with Mercks blockbuster cancer drug, Keytruda
- Imugene acquires from Precision Therapeutics a successful allogenic therapy Azer Cel, in the late stages of the drugs successful development into blood cancers, in combination with a manufacturing plant to process the drug
- Imugene’s CF33 Trial into late stage TNBC patients in the US illustrates signs of necrosis (i.e., cell death),
- Imugene progresses through each and every cohort in their 100 patient strong Vaxinia (MAST) Trial for the treatment of solid tumour cancer patients, as both a stand alone monotherapy, and in combination with Mercks’s Keytruda, and
- Imugene announces a collaboration between RenovoRx’s trans-arterial drug delivery system and their CF33 oncolytic virus platform, with the potential to facilitate treatment of difficult-to-access cancers and help patients
For those like Hopper and Chong with skin still in the game nothing has changed. It’s business as usual, with each and every immunotherapy treatment going through the motions, from strength to strength as it were. Proof of concept is evident within the company’s B cell platform. Studies exemplify the potential of Oncarlytics as a treatment arm. Azer cel adds to the Oncarlytics opportunity. But most importantly Imugene’s flagship candidates , CF33 and VAXINIA, have been found to be safe once administered to humans, and exhibiting positive signs of efficacy.
As many are aware, my prediction was for IMU to hit $1 by the years end. The stock clearly has a long way to climb to reach such lofty heights. Particularly when one considers the full Vaxinia picture may not be revealed at this stage of play. Yet irrespective of dollars and cents I feel that like Shakespeare’s "Much ado about nothing,” there are a dozen reasons (see above) Imugene is set to climb from the depths of perceived deception, toward the happy ending many shareholders have dreamed of.
In “Much ado nothing” even Hero, who is particularly loyal, has her loyalty called into question by Claudio due to some trickery on Don John's part. As with Imugene, along the way many, (including me), have felt their loyalty waiver, under the pressure of a freecall in the company’s share price. But despite the at times perceived under performance of those in charge, one cannot deny Imugene’s fundamental position is as strong now as it ever was. There may be a few more chapters between now and the happy ending I envisaged, but in the end I’m confident many of our existing shareholders concerns shall amount to “Much ado about nothing”.
DYOR Seek investment advice as and when required Opinions only
(20min delay)